4DMT Grants 35,200 RSUs to 5 New Employees Under Nasdaq Inducement Rule
Updated
Updated · Yahoo Finance · Aug 14
4DMT Grants 35,200 RSUs to 5 New Employees Under Nasdaq Inducement Rule
3 articles · Updated · Yahoo Finance · Aug 14
Summary
August 11 grants gave five new non-executive hires at 4D Molecular Therapeutics a total of 35,200 restricted stock units, the company said Friday.
The awards came from 4DMT's amended 2025 Employment Inducement Award Plan and were approved by the board compensation committee to attract the new employees under Nasdaq Rule 5635(c)(4).
4DMT is a late-stage biotech whose lead candidate, 4D-150, is in Phase 3 development for wet age-related macular degeneration, while 4D-710 targets cystic fibrosis.
The company said all of its product candidates remain in clinical or preclinical development and have not been approved for marketing by U.S. regulators.